2. Search Result
Search Result
Results for "

LDHB

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Recombinant Proteins

2

Antibodies

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS07572
    LDHB Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LDHB Human Pre-designed siRNA Set A contains three designed siRNAs for LDHB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LDHB Human Pre-designed siRNA Set A
    LDHB Human Pre-designed siRNA Set A
  • HY-147216
    AXKO-0046
    4 Publications Verification

    		 Lactate Dehydrogenase Cancer
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism .
    AXKO-0046
  • HY-152261
    MS6105

    		PROTACs Cancer
    MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MS6105
  • HY-147216A
    AXKO-0046 dihydrochloride
    4 Publications Verification

    		 Lactate Dehydrogenase Metabolic Disease Inflammation/Immunology Cancer
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism .
    AXKO-0046 dihydrochloride
  • HY-111108
    LDH-IN-1
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
    LDH-IN-1
  • HY-100742A
    (R)-GNE-140
    Maximum Cited Publications
    15 Publications Verification

    		 Lactate Dehydrogenase Cancer
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
    (R)-GNE-140
  • HY-W040118
    Galloflavin
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
    Galloflavin
  • HY-RS16989
    Ldhb Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ldhb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldhb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ldhb Mouse Pre-designed siRNA Set A
    Ldhb Mouse Pre-designed siRNA Set A
  • HY-RS23432
    Ldhb Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ldhb Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldhb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ldhb Rat Pre-designed siRNA Set A
    Ldhb Rat Pre-designed siRNA Set A
  • HY-162629
    LDHA-IN-7

    		Lactate Dehydrogenase Cancer
    LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
    LDHA-IN-7
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Apoptosis Cancer
    NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
    NHI-2
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: